After tackling Covid-19 with AstraZeneca, Oxford's Jenner Institute is hard at work on a different kind of vaccine

Nicole DeFeudis

Editor

The institute behind AstraZeneca’s Covid-19 vaccine with Oxford University just got funding to pursue a different kind of vaccine for an infection that’s not quite …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After tackling Covid-19 with AstraZeneca, Oxford's Jenner Institute is hard at work on a different kind of vaccine

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter tack­ling Covid-19 with As­traZeneca, Ox­ford's Jen­ner In­sti­tute is hard at work on a dif­fer­ent kind of vac­cine

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After tackling Covid-19 with AstraZeneca, Oxford's Jenner Institute is hard at work on a different kind of vaccine